1. Increased Visceral Adipose Tissue and Hyperinsulinemia Raise the Risk for Recurrence of Non-B Non-C Hepatocellular Carcinoma after Curative Treatment
   Kenji Imai et al, 2021, Cancers CrossRef
2. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end
   Cristina Maria Muzica et al, 2020, World Journal of Gastroenterology CrossRef
3. Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics
   Luca Rinaldi et al, 2020, Cancers CrossRef
4. Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures
   Reem Ezzat et al, 2021, World Journal of Gastrointestinal Oncology CrossRef
5. Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate
   Ahmed Kamal et al, 2022, World Journal of Clinical Cases CrossRef
6. Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group
   Toshie Mashiba et al, 2022, Journal of Viral Hepatitis CrossRef
7. Hepatitis C Virus-Related One-Year Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial
   Ahmed Kamal et al, 2024, Journal of Gastrointestinal Cancer CrossRef
8. Lebendspende Lebertransplantation für erwachsene Empfänger
   Utz Settmacher et al, 2023, Organtransplantation mit Lebendspende CrossRef
9. Predictive Factors for Hepatocellular Carcinoma Development after Direct-Acting Antiviral Treatment of HCV
   Zuzana Macek Jilkova et al, 2021, Livers CrossRef